MSI2 and non-small cell lung carcinoma: Our ex vivo IHC data revealed that that co-injection of MSI2-positive CAFs in an NSCLC xenograft promoted EMT in NSCLC tumors, whereas MSI2-depleted CAFs lacked this ability (Fig. 6A), which was further validated in vitro (Fig. 6B–D; Additional file 2: Fig. S14).